loading
Schlusskurs vom Vortag:
$2.72
Offen:
$2.75
24-Stunden-Volumen:
173.73K
Relative Volume:
0.37
Marktkapitalisierung:
$264.13M
Einnahmen:
$64.70M
Nettoeinkommen (Verlust:
$-123.43M
KGV:
-11.35
EPS:
-0.24
Netto-Cashflow:
$-95.23M
1W Leistung:
-14.80%
1M Leistung:
+9.40%
6M Leistung:
-7.91%
1J Leistung:
+4.79%
1-Tages-Spanne:
Value
$2.65
$2.81
1-Wochen-Bereich:
Value
$2.63
$3.28
52-Wochen-Spanne:
Value
$1.87
$4.27

Poseida Therapeutics Inc Stock (PSTX) Company Profile

Name
Firmenname
Poseida Therapeutics Inc
Name
Telefon
858-779-3100
Name
Adresse
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Name
Mitarbeiter
350
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PSTX's Discussions on Twitter

Vergleichen Sie PSTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
PSTX 2.725 264.13M 64.70M -123.43M -95.23M -0.24
VRTX 450.44 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.43 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.53 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.84 24.89B 3.30B -501.07M 1.03B 11.54

Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-01-04 Eingeleitet H.C. Wainwright Buy
2022-01-07 Eingeleitet Cantor Fitzgerald Overweight
2021-05-18 Eingeleitet BTIG Research Buy
2020-08-04 Eingeleitet BofA Securities Buy
2020-08-04 Eingeleitet Piper Sandler Overweight
2020-08-04 Eingeleitet William Blair Outperform
Alle ansehen

Poseida Therapeutics Inc Aktie (PSTX) Neueste Nachrichten

pulisher
09:13 AM

Poseida Therapeutics to Present at Two Upcoming Investor Conferences - Marketscreener.com

09:13 AM
pulisher
05:50 AM

Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

05:50 AM
pulisher
Nov 19, 2024

Poseida Therapeutics (NASDAQ:PSTX) Earns Buy Rating from HC Wainwright - Defense World

Nov 19, 2024
pulisher
Nov 16, 2024

Poseida Therapeutics Provides Update on Cell Therapy Research ProgramsOn November 14, 2024, Poseida Therapeutics, Inc. issued a press release providing an update on its cell therapy research and development programs. Members of the management - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Poseida Therapeutics offers preclinical highlights of CAR T pipeline - BioWorld Online

Nov 15, 2024
pulisher
Nov 15, 2024

Where Poseida Therapeutics Stands With Analysts - Benzinga

Nov 15, 2024
pulisher
Nov 15, 2024

Poseida Therapeutics (NASDAQ:PSTX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline - PR Newswire

Nov 14, 2024
pulisher
Nov 13, 2024

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know - MSN

Nov 13, 2024
pulisher
Nov 12, 2024

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Poseida Therapeutics’ (PSTX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Poseida Therapeutics (PSTX) to Present at Major Stifel, Piper Sandler Healthcare Conferences | PSTX Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 09, 2024

HC Wainwright Reiterates Buy Rating for Poseida Therapeutics (NASDAQ:PSTX) - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 08, 2024
pulisher
Nov 08, 2024

Poseida Therapeutics Reports Strong Q3 2024 Progress - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - PR Newswire

Nov 07, 2024
pulisher
Nov 05, 2024

Poseida Therapeutics to present cancer cell therapy data at SITC, ASH - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - Lelezard

Nov 05, 2024
pulisher
Nov 05, 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 – Company AnnouncementFT.com - Financial Times

Nov 05, 2024
pulisher
Nov 01, 2024

Poseida Therapeutics (STU:2RZ) Degree of Operating Leverage : -9.17 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024
pulisher
Oct 30, 2024

Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 30, 2024
pulisher
Oct 26, 2024

Poseida Therapeutics Receives Regenerative Medicine Advanced The - GuruFocus.com

Oct 26, 2024
pulisher
Oct 24, 2024

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire

Oct 24, 2024
pulisher
Oct 23, 2024

VRTX: 3 Pharma Stocks to Watch as Gene Therapy Gains Momentum - StockNews.com

Oct 23, 2024
pulisher
Oct 19, 2024

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30% - Simply Wall St

Oct 19, 2024
pulisher
Oct 18, 2024

Third development candidate nominated under Poseida and Roche’s allogeneic CAR T collaboration - BioWorld Online

Oct 18, 2024
pulisher
Oct 17, 2024

Poseida shares hold as analyst reiterates buy rating on MM study - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Nominates New Development Candidate Under Its Collaboration With Roche - Contract Pharma

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida advances with new CAR-T therapy candidate - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - StockTitan

Oct 17, 2024
pulisher
Oct 16, 2024

Quarterly Metrics: Quick and Current Ratios for Poseida Therapeutics Inc (PSTX) - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors - The Manila Times

Oct 15, 2024
pulisher
Oct 14, 2024

The Anatomy Of Astellas And Poseida's CAR-T Deal - In Vivo

Oct 14, 2024
pulisher
Oct 10, 2024

PSTXPoseida Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 10, 2024
pulisher
Oct 10, 2024

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™

Oct 10, 2024
pulisher
Oct 07, 2024

Ratio Examination: Poseida Therapeutics Inc (PSTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Poseida Therapeutics Inc (PSTX) deserves closer scrutiny - US Post News

Oct 07, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - IT News Online

Oct 03, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics (STU:2RZ) Long-Term Capital Lease Obli - GuruFocus.com

Oct 03, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics (STU:2RZ) Net Change in Cash : €-18.49 Mil (TTM As of Jun. 2024) - GuruFocus.com

Oct 03, 2024
pulisher
Oct 03, 2024

Anchoring Your Portfolio: Is PSTX Stock a Safe Harbor? - The InvestChronicle

Oct 03, 2024
pulisher
Oct 02, 2024

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Renaissance Technologies LLC - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma - Genetic Engineering & Biotechnology News

Oct 02, 2024
pulisher
Oct 01, 2024

A new trading data show Poseida Therapeutics Inc (PSTX) is showing positive returns. - SETE News

Oct 01, 2024
pulisher
Oct 01, 2024

Poseida stock supported by strong data from P-BCMA-ALLO-1, says BTIG - Investing.com South Africa

Oct 01, 2024
pulisher
Sep 30, 2024

Piper Sandler maintains Overweight rating on Poseida Therapeutics shares - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Poseida Therapeutics reveals promising trial results for myeloma treatment - Investing.com

Sep 30, 2024

Finanzdaten der Poseida Therapeutics Inc-Aktie (PSTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):